The Jiangsu Biobank for the Prevention and Control of Diabetes (JBPCD) in China
- PMID: 39565534
- DOI: 10.1007/s10654-024-01172-y
The Jiangsu Biobank for the Prevention and Control of Diabetes (JBPCD) in China
Abstract
The Jiangsu Biobank for the Prevention and Control of Diabetes (JBPCD) is a community-based prospective cohort study initiated in Jiangsu province, to examine the burden of complications associated with type 2 diabetes mellitus (T2DM). This study aims to better understand the incidence, risk factors, and long-term outcomes of T2DM complications to inform prevention and control strategies. From October 2013 to July 2014, 20,053 T2DM patients (7,862 males and 12,191 females) were recruited from Suzhou city and Huai'an city. Baseline data were collected through questionnaire survey, physical examination and biochemical testing, with blood samples stored in a biobank. The follow-up focused on the incidence and mortality related to T2DM complications, linked to national and local medical datasets. Between August 2019 and October 2020, the repeated assessments were completed for 13,973 participants, including questionnaire, physical examination and repeated blood collection. The study identified 1,479 new cancer cases and 3,324 cardiovascular disease cases, with an overall mortality rate of 25.66 per 1,000 person-years. JBPCD welcomes research collaborations and data access requests via email. Currently, there are no plans to provide cohort data for free public access, but specific proposals for further collaboration are welcome. For further information and collaboration, please email [jswuming@vip.sina.com] and [sc@njmu.edu.cn].
Keywords: Cancer; Cardiovascular disease; Cohort; Complications; Type 2 diabetes mellitus.
© 2024. Springer Nature B.V.
Conflict of interest statement
Declarations. Ethical approval: This study was approved by the Ethics Board of Jiangsu Provincial Centre for Disease Control and Prevention (2013026 and JSJK2018-B018-01). Conflict of interest: The authors declare that they have no conflicts of interest.
References
-
- Ahmad E, Lim S, Lamptey R, Webb DR, Davies MJ. Type 2 diabetes. Lancet. 2022;400(10365):1803–20. https://doi.org/10.1016/S0140-6736(22)01655-5 . - DOI - PubMed
-
- Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. https://doi.org/10.1016/j.diabres.2021.109119 . - DOI - PubMed
-
- Collaborators GBDD. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023;402(10397):203–34. https://doi.org/10.1016/S0140-6736(23)01301-6 . - DOI
-
- Mansour A, Mousa M, Abdelmannan D, Tay G, Hassoun A, Alsafar H. Microvascular and macrovascular complications of type 2 diabetes mellitus: Exome wide association analyses. Front Endocrinol (Lausanne). 2023;14:1143067. https://doi.org/10.3389/fendo.2023.1143067 . - DOI - PubMed
-
- Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88–98. https://doi.org/10.1038/nrendo.2017.151 . - DOI - PubMed
MeSH terms
Grants and funding
- K201105/Jiangsu Province Leading Talents and Innovation Team Program
- BRA2020090/Jiangsu Provincial Fifth "333 Project"
- M2020085/Jiangsu Provincial Health Commission Medical Research Project Approval
- H2023022/Jiangsu Provincial Health Commission Medical Research Project Approval
- SS202010/Suzhou Program of Science & Technology Development
LinkOut - more resources
Full Text Sources
Medical